Pregabalin Capsule
Product Images NDC 58118-1465

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 58118-1465). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 100mg Capsule 30ct Blister Card (Prega 100mg 90s A)

Label for Pregabalin 100 mg capsule from Clinical Solutions Wholesale. The label displays the NDC number 58118-1465-8, quantity of 30 capsules, manufacturer Ascend Laboratories, LLC, and includes batch and expiration details. Repackaged and distributed by Clinical Solutions Wholesale, LLC in Franklin, TN.*

FDA Label Image

Pregabalin 150mg Capsule 30ct Blister Card (Prega 150mg 90s A)

Label for Pregabalin 150 mg capsules by Clinical Solutions Wholesale. The label includes NDC 58118-1466-8, with a quantity of 30 capsules. Manufacturer is Ascend Laboratories, LLC. Additional details include the manufacturing NDC, lot number SAMPLE123, batch number SAMPLE456, expiration date February 2027, and a repack location in Franklin, TN. The label features barcodes and a QR code.*

FDA Label Image

Pregabalin 200mg Capsule 30ct Blister Card (Prega 200mg 500s A)

Pregabalin 200 mg Capsule packaging label from Clinical Solutions Wholesale, LLC. The label includes NDC 58118-1467-8, quantity of 30 capsules, and lists Ascend Laboratories, LLC as the manufacturer in Parsippany, NJ. It shows batch number, expiration date February 2027, and other manufacturing details.*

FDA Label Image

Pregabalin 50mg Capsule 30ct Blister Card (Prega 50mg 500s A)

Pregabalin 50 mg oral capsule packaging label by Clinical Solutions Wholesale, LLC. The label shows NDC 58118-1463-8, quantity 30 capsules, and manufacturing details including lot numbers and expiration date of February 2027. It includes barcodes and distribution information from Parsippany, NJ, USA.*

FDA Label Image

Pregabalin 75mg Capsule 30ct Blister Card (Pregabalin 75 90 1)

Label for Pregabalin 75 mg capsule by Clinical Solutions Wholesale, LLC. The label shows the NDC 58118-1464-8 and indicates a quantity of 30 capsules. The drug is manufactured by Ascend Laboratories, LLC, Parsippany, NJ, USA. The label includes manufacturing details, batch number SAMPLE163, expiration date February 2027, and a QR code.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This panel presents a formula for calculating creatinine clearance (CLCr), incorporating factors such as age, weight, serum creatinine levels, and a multiplier for female patients. The formula uses units including years, kilograms, and mg/dL for serum creatinine.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

A bar chart displaying responder rates in percentage on the vertical axis for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The chart shows increasing responder rates from 22.6% for Placebo, 29.1% for 2.5 mg/kg/day, to 40.6% for 10 mg/kg/day, with sample sizes of 93, 103, and 96, respectively.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph showing responder rates (%) from two clinical studies, Study E1 and Study E3, comparing placebo with various doses of Pregabalin. The graph shows increasing responder rates with higher doses of Pregabalin (50 mg to 600 mg daily) given either BID or TID, with statistically significant differences versus placebo indicated by asterisks.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph showing seizure reduction as median percent change from baseline versus dose (mg/day) for Pregabalin in various studies. The x-axis represents dose levels from 0 to 600 mg/day, and the y-axis shows seizure reduction from 0 to 60 percent. Four study groups are plotted with different symbols and dashed lines indicating dosing schedules (BID or TID). Significant p-values are annotated at several points.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Four lines represent different Pregabalin dosages (25 mg, 100 mg, 200 mg, each taken three times a day) and a placebo group. The graph illustrates how patient improvement varies across different dosage levels compared to placebo.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line chart showing the percent of subjects improved over percent improved from baseline to Week 12 BOCF for Pregabalin and Placebo groups. The x-axis represents percent improvement from baseline to Week 12, while the y-axis shows the percent of subjects improved. Two lines compare the effectiveness of Pregabalin versus Placebo.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent of subjects improved from baseline to Week 16 using the Hamilton Depression Rating Scale (HDRS). The x-axis shows percent improvement from baseline to Week 16 HDRS, and the y-axis indicates percent of subjects improved. Two lines represent Pregabalin and Placebo, with Pregabalin showing consistently higher improvement percentages across the range compared to Placebo.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line chart depicting the percentage of patients improved according to the percent improvement in pain from baseline. Two lines compare outcomes for Pregabalin 100 mg three times a day versus placebo across various levels of pain improvement.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, showing their relative patient improvements over the range.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating varying levels of pain improvement across these groups.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 50 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The x-axis represents percent improvement in pain from baseline (0-100%), and the y-axis shows the percent of patients improved (0-100%). Two vertical lines mark specific improvement thresholds at 30% and 50%.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at daily doses of 600 mg, 450 mg, and 300 mg to a placebo. The legend differentiates the lines representing each dose and placebo.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve graph comparing the estimated percentage of subjects without LTR (likely an event or outcome) over 180 days. The graph shows two curves: one for Pregabalin and one for Placebo, with the Pregabalin group maintaining a higher percentage of subjects without LTR throughout the period.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin, illustrating its molecular arrangement with an amino group (NH2) and a carboxylic acid group (CO2H) attached to the carbon skeleton.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.